NeupoNET aims to evaluate interest of G-CSF in the treatment of Toxic Epidermal necrolysis. This is a prospective randomized controlled trial.

Patients will be allocated in a treatment group (receiving an injection of 5 microg/kg/d of G-CSF during 5 consecutive days) or in a placebo group. Patients will be randomized at admission and will be followed until 3 months after discharge.

Inclusion Criteria:

• Toxic epidermal necrolysis with SCORTEN 1 to 5 at admission

Exclusion Criteria:

• Toxic epidermal necrolysis with SCORTEN 6 or 7 at admission
• Hypercoagulable state
• Cardiac or peripheral arterial disease
• Active malignancy
• Myelodysplastic syndrome or hematological malignancy
• Fructose intolerance
• Pregnancy
• Patient refusal